The Form 4 filing, a report used to disclose an insider's stock trades, was filed on October 30, 2026. The purchases took place on October 28, two days before the filing date.
The filing identifies James Healy as a director of Rapport Therapeutics (RAPP). The four purchase transactions involve one insider and are covered by one filing.
Transaction details
| Transaction | |
|---|---|
| Date of Earliest Transaction | 2026-10-28 |
| Date of Latest Transaction | 2026-10-28 |
| Buy/Sell | buy |
| Transaction Count | 4 |
| Shares Transacted | 969,480 |
| Price | $21.00 |
| Total Transaction Value | $20,359,080.00 |
| Insider | |
| Ticker Symbol | RAPP |
| Company | Rapport Therapeutics, Inc. |
| Insider Name | HEALY JAMES |
| Insider Title | Director |
| Sector - Industry | Other - Unclassified |
| Holdings | |
| Total Shares Owned After Transaction | 2,815,707 |
| Position Size Change | 34.43% |
| Filing | |
| Filing Date | 2026-10-30 |
| SEC Link | View filing |
FAQ
What type of transaction is this?
These were share purchases, reported under transaction code P. The available details do not say whether the shares were bought on a stock exchange or through a private deal.
What was the average price of the transaction?
The reported average price was $21.00 per share across the four purchases. Separate prices for each purchase were not available.
How did this transaction affect the insider's holdings?
James Healy bought 969,480 shares and reported owning 2,815,707 shares afterward. The newly bought shares made up 34.43% of the shares he reported owning after the trades.
What's the total transaction value?
The total transaction value was $20,359,080.00. That amount covers all four purchases reported for October 28, 2026.
Are there any special circumstances around this transaction?
The available transaction information did not identify a special arrangement. Footnote text was not available for this report, so any further terms or explanations remain unknown.
For research purposes only; not investment advice.